LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Atvērts

SektorsVeselības aprūpe

4.19 -1.64

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.16

Max

4.43

Galvenie mērījumi
By Trading Economics
Ienākumi	-26M -34M
Pārdošana	-9.4M 200M
EPS	-0.09
Peļņas marža	-17.016
Darbinieki	2,700
EBITDA	43M -18M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+75.23% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-62M 404M
Iepriekšējā atvēršanas cena	5.83
Iepriekšējā slēgšanas cena	4.19

Ziņu noskaņojums

By Acuity

15%

85%

26 / 344 Rangs Healthcare

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. jūn. 20:30 UTC

Peļņas

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026. g. 2. jūn. 23:58 UTC

Tirgus saruna

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026. g. 2. jūn. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026. g. 2. jūn. 23:41 UTC

Tirgus saruna

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026. g. 2. jūn. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026. g. 2. jūn. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026. g. 2. jūn. 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026. g. 2. jūn. 22:57 UTC

Tirgus saruna

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026. g. 2. jūn. 22:50 UTC

Tirgus saruna

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026. g. 2. jūn. 21:07 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. jūn. 21:07 UTC

Tirgus saruna

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026. g. 2. jūn. 21:00 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 2. jūn. 20:46 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:38 UTC

Peļņas

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026. g. 2. jūn. 20:21 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:12 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Product Rev $594M

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Loss $177M >PANW

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

75.23% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 75.23%

Augstākais 10 USD

Zemākais 5.5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

26 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.